Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. 2013

Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
Infection Innovative Medicine, AstraZeneca Pharmaceuticals, 35 Gatehouse Lane, Waltham, MA 02451, USA.

Targeting viral polymerases has been a proven and attractive strategy for antiviral drug discovery. Herein we describe our effort in improving the antiviral activity and physical properties of a series of benzothienoazepine compounds as respiratory syncytial virus (RSV) RNA polymerase inhibitors. The antiviral activity and spectrum of this class was significantly improved by exploring the amino substitution of the pyridine ring, resulting in the discovery of the most potent RSV A polymerase inhibitors reported to date.

UI MeSH Term Description Entries
D012136 Respiratory Syncytial Viruses A group of viruses in the PNEUMOVIRUS genus causing respiratory infections in various mammals. Humans and cattle are most affected but infections in goats and sheep have also been reported. Chimpanzee Coryza Agent,Orthopneumovirus,RSV Respiratory Syncytial Virus,Chimpanzee Coryza Agents,Coryza Agent, Chimpanzee,Orthopneumoviruses,Respiratory Syncytial Virus,Syncytial Virus, Respiratory,Virus, Respiratory Syncytial
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D012321 DNA-Directed RNA Polymerases Enzymes that catalyze DNA template-directed extension of the 3'-end of an RNA strand one nucleotide at a time. They can initiate a chain de novo. In eukaryotes, three forms of the enzyme have been distinguished on the basis of sensitivity to alpha-amanitin, and the type of RNA synthesized. (From Enzyme Nomenclature, 1992). DNA-Dependent RNA Polymerases,RNA Polymerases,Transcriptases,DNA-Directed RNA Polymerase,RNA Polymerase,Transcriptase,DNA Dependent RNA Polymerases,DNA Directed RNA Polymerase,DNA Directed RNA Polymerases,Polymerase, DNA-Directed RNA,Polymerase, RNA,Polymerases, DNA-Dependent RNA,Polymerases, DNA-Directed RNA,Polymerases, RNA,RNA Polymerase, DNA-Directed,RNA Polymerases, DNA-Dependent,RNA Polymerases, DNA-Directed
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
March 2002, Antimicrobial agents and chemotherapy,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
May 2021, Antimicrobial agents and chemotherapy,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
June 2020, ACS medicinal chemistry letters,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
April 2001, Bioorganic & medicinal chemistry letters,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
July 2019, Journal of medicinal chemistry,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
May 2020, ACS infectious diseases,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
October 2020, ACS infectious diseases,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
January 2020, Nature communications,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
December 2014, Journal of medicinal chemistry,
Hui Xiong, and Melinda Foulk, and Lisa Aschenbrenner, and Jun Fan, and Choi-Lai Tiong-Yip, and Kenneth D Johnson, and Demetri Moustakas, and Paul R Fleming, and Dean G Brown, and Minli Zhang, and Douglas Ferguson, and Dedong Wu, and Qin Yu
March 2014, Journal of medicinal chemistry,
Copied contents to your clipboard!